Robert J. More - May 22, 2023 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Director
Signature
/s/ Sung Lee, Attorney-in-Fact
Stock symbol
VIR
Transactions as of
May 22, 2023
Transactions value $
$0
Form type
4
Date filed
5/24/2023, 02:41 PM
Previous filing
Jun 15, 2022
Next filing
Jun 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +6.03K +15.43% $0.00 45.1K May 22, 2023 Direct
holding VIR Common Stock 489K May 22, 2023 See footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +12.1K $0.00 12.1K May 22, 2023 Common Stock 12.1K $25.74 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are held by Alta Partners NextGen Fund I, L.P. (APNG 1). The reporting person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the reporting person may be deemed to beneficially own the shares held by APNG 1. However, the reporting person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.